Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

A Quantitative Microtiter Assay for Sialylated Glycoform Analyses Using Lectin Complexes.

Srinivasan K, Roy S, Washburn N, Sipsey SF, Meccariello R, Meador JW 3rd, Ling LE, Manning AM, Kaundinya GV.

J Biomol Screen. 2015 Jul;20(6):768-78. doi: 10.1177/1087057115577597. Epub 2015 Apr 7.

2.

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.

Washburn N, Schwab I, Ortiz D, Bhatnagar N, Lansing JC, Medeiros A, Tyler S, Mekala D, Cochran E, Sarvaiya H, Garofalo K, Meccariello R, Meador JW 3rd, Rutitzky L, Schultes BC, Ling L, Avery W, Nimmerjahn F, Manning AM, Kaundinya GV, Bosques CJ.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1297-306. doi: 10.1073/pnas.1422481112. Epub 2015 Mar 2. Erratum in: Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4339.

3.

Chinese hamster ovary cells can produce galactose-α-1,3-galactose antigens on proteins.

Bosques CJ, Collins BE, Meador JW 3rd, Sarvaiya H, Murphy JL, Dellorusso G, Bulik DA, Hsu IH, Washburn N, Sipsey SF, Myette JR, Raman R, Shriver Z, Sasisekharan R, Venkataraman G.

Nat Biotechnol. 2010 Nov;28(11):1153-6. doi: 10.1038/nbt1110-1153. No abstract available. Erratum in: Nat Biotechnol. 2011 May;29(5):459.

4.

Thioether benzenesulfonamide inhibitors of carbonic anhydrases II and IV: structure-based drug design, synthesis, and biological evaluation.

Vernier W, Chong W, Rewolinski D, Greasley S, Pauly T, Shaw M, Dinh D, Ferre RA, Meador JW 3rd, Nukui S, Ornelas M, Paz RL, Reyner E.

Bioorg Med Chem. 2010 May 1;18(9):3307-19. doi: 10.1016/j.bmc.2010.03.014. Epub 2010 Mar 11. Erratum in: Bioorg Med Chem. 2010 Oct 1;18(19):7144. Meador, James W 3rd [added]; Paz, Robert L [added].

PMID:
20363633
5.

Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.

Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW 3rd, Matthews DA, Patick AK.

Antimicrob Agents Chemother. 2005 Feb;49(2):619-26.

6.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW 3rd, Ferre RA.

J Med Chem. 2003 Oct 9;46(21):4572-85.

PMID:
14521419
7.

Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease.

Johnson TO, Hua Y, Luu HT, Brown EL, Chan F, Chu SS, Dragovich PS, Eastman BW, Ferre RA, Fuhrman SA, Hendrickson TF, Maldonado FC, Matthews DA, Meador JW 3rd, Patick AK, Reich SH, Skalitzky DJ, Worland ST, Yang M, Zalman LS.

J Med Chem. 2002 May 9;45(10):2016-23.

PMID:
11985469
8.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Tuntland T, Lee CA, Patick AK, Matthews DA, Hendrickson TF, Kosa MB, Liu B, Batugo MR, Gleeson JP, Sakata SK, Chen L, Guzman MC, Meador JW 3rd, Ferre RA, Worland ST.

J Med Chem. 2002 Apr 11;45(8):1607-23.

PMID:
11931615
9.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Johnson TO, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Hou X, Meador JW, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 2002 Mar 11;12(5):733-8.

PMID:
11858991
10.

Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.

Webber SE, Marakovits JT, Dragovich PS, Prins TJ, Zhou R, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Srinivasan B, Moran T, Ford CE, Brothers MA, Harr JE, Meador JW 3rd, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 2001 Oct 22;11(20):2683-6.

PMID:
11591501
11.

Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors.

Dragovich PS, Zhou R, Webber SE, Prins TJ, Kwok AK, Okano K, Fuhrman SA, Zalman LS, Maldonado FC, Brown EL, Meador JW 3rd, Patick AK, Ford CE, Brothers MA, Binford SL, Matthews DA, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 2000 Jan 3;10(1):45-8.

PMID:
10636240
12.

In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.

Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST.

Antimicrob Agents Chemother. 1999 Oct;43(10):2444-50.

13.

Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11000-7.

14.

Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids.

Dragovich PS, Webber SE, Prins TJ, Zhou R, Marakovits JT, Tikhe JG, Fuhrman SA, Patick AK, Matthews DA, Ford CE, Brown EL, Binford SL, Meador JW 3rd, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 1999 Aug 2;9(15):2189-94.

PMID:
10465543
15.

Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides.

Dragovich PS, Zhou R, Skalitzky DJ, Fuhrman SA, Patick AK, Ford CE, Meador JW 3rd, Worland ST.

Bioorg Med Chem. 1999 Apr;7(4):589-98.

PMID:
10353638
16.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.

Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador JW 3rd, Ferre RA, Harr JE, Kosa MB, Worland ST.

J Med Chem. 1999 Apr 8;42(7):1213-24.

PMID:
10197965
17.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Fuhrman SA, Patick AK, Matthews DA, Ford CE, Meador JW 3rd, Ferre RA, Worland ST.

J Med Chem. 1999 Apr 8;42(7):1203-12.

PMID:
10197964
18.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.

Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Reich SH, Marakovits JT, Prins TJ, Zhou R, Tikhe J, Littlefield ES, Bleckman TM, Wallace MB, Little TL, Ford CE, Meador JW 3rd, Ferre RA, Brown EL, Binford SL, DeLisle DM, Worland ST.

J Med Chem. 1998 Jul 16;41(15):2819-34.

PMID:
9667971
19.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.

Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Reich SH, Prins TJ, Marakovits JT, Littlefield ES, Zhou R, Tikhe J, Ford CE, Wallace MB, Meador JW 3rd, Ferre RA, Brown EL, Binford SL, Harr JE, DeLisle DM, Worland ST.

J Med Chem. 1998 Jul 16;41(15):2806-18.

PMID:
9667970
20.

Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.

Webber SE, Okano K, Little TL, Reich SH, Xin Y, Fuhrman SA, Matthews DA, Love RA, Hendrickson TF, Patick AK, Meador JW 3rd, Ferre RA, Brown EL, Ford CE, Binford SL, Worland ST.

J Med Chem. 1998 Jul 16;41(15):2786-805.

PMID:
9667969
21.

Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.

Webber SE, Tikhe J, Worland ST, Fuhrman SA, Hendrickson TF, Matthews DA, Love RA, Patick AK, Meador JW, Ferre RA, Brown EL, DeLisle DM, Ford CE, Binford SL.

J Med Chem. 1996 Dec 20;39(26):5072-82.

PMID:
8978838
22.

pTRIPLEscript: a novel cloning vector for generating in vitro transcripts from tandem promoters for SP6, T7 and T3 RNA polymerase.

Meador JW 3rd, McElroy HE, Pasloske BL, Milburn SC, Winkler MM.

Biotechniques. 1995 Jan;18(1):152-7,.

PMID:
7702842
23.

Polymorphism in the promoter region of HLA-DRB genes.

Perfetto C, Zacheis M, McDaid D, Meador JW 3rd, Schwartz BD.

Hum Immunol. 1993 Jan;36(1):27-33.

PMID:
8458736
24.

Comparative in vitro evaluations of vascular graft compliance during dynamic loading.

Igo SR, Meador JW, Frazier OH.

ASAIO Trans. 1988 Jul-Sep;34(3):785-8.

PMID:
3196599
25.

THE DESIGN AND FABRICATION OF A NEW TOTAL ARTIFICIAL HEART.

Cheng K, Meador JW, Serrato MA, Akutsu T.

Cardiovasc Dis. 1977;4(1):7-17. No abstract available.

26.

Peripheral vascular effects of glucagon, acetylocholine and dopamine with an implanted total artificial heart (TAH).

Kaku K, Nagai I, Hongo T, Vakamudi AK, Meador JW, Akutsu T.

Trans Am Soc Artif Intern Organs. 1977;23:611-6.

PMID:
910390
27.

Peak and phasic changes of power utilization of a total artificial heart in response to after-load.

Meador JW, Hongo T, Kaku K, Vakamudi AK, Akutsu T.

Trans Am Soc Artif Intern Organs. 1977;23:512-8. No abstract available.

PMID:
910374

Supplemental Content

Loading ...
Support Center